Company Analysis

Relay Therapeutics, Inc. (RLAY)

Nasdaq: RLAY · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2020
Grade5.5
◀ Past 4.7● Present 6.6▶ Future 5.2
1 est.

Who runs Relay Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Patel Sanjiv
President and CEO. First filing Jul 2020, latest Oct 8, 2026, 19 filings in all.
Officers reporting now
4
of 11 people with a filing in the last fifteen months
Directors reporting now
7
17 people on the record since 2020
Officerssales are open-market, Oct 30, 2025 to Oct 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Bergstrom Donald APresident, R&DJul 2020Oct 30, 20268 · $2.2M
Catinazzo ThomasChief Financial OfficerJul 2020Oct 30, 202618 · $5.4M
Rahmer PeterSee remarksJan 2023Oct 30, 20267 · $1.2M
Patel SanjivPresident and CEOJul 2020Oct 8, 20266 · $4.5M
Directorssales are open-market, Oct 30, 2025 to Oct 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Borisy AlexisdirectorJul 2020Jun 10, 2026none
Coats LonneldirectorNov 2025Jun 10, 2026none
Dable Habib JdirectorNov 2025Jun 10, 2026none
Hill Linda AdirectorJul 2020Jun 10, 2026none
Ingram Douglas SdirectorJul 2020Jun 10, 2026none
Mazumdar ClairedirectorJun 2025Jun 10, 2026none
Murcko MarkdirectorJul 2020Jun 10, 2026none
Owners of more than 10% of a classsales are open-market, Oct 30, 2025 to Oct 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Sb Investment Advisers (Uk) Ltd10% ownerJul 2020Aug 28, 20261 · $116M
Softbank Vision Fund (Aiv M2) L.P.10% ownerJul 2020Aug 28, 2026none
Svf Pauling (Cayman) Ltd10% ownerJul 2020Aug 28, 2026none
Earlier names on the record18, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RLAY · research, not advice